FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 261 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR New study supports extending cervical screening intervals for people who test... May 31, 2022 FOCUS4: Learning from a landmark clinical trial April 25, 2023 Qué saber al buscar información sobre el cáncer en línea: perspectiva... August 11, 2022 癌症可以在家族成员中被遗传吗？ October 13, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... Talk Cancer: How to have conversations that could save lives Tattoo Artist Offers Free Nipple Tattoos To Breast Cancer Patients That...
